Threat actors are operationalizing AI to scale and sustain malicious activity, accelerating tradecraft and increasing risk for defenders, as illustrated by recent activity from North Korean groups ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

The technology giant and third-party security vendors are plotting an ambitious overhaul of how their products interoperate.

Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsSanjiv Patel - CEO, President ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

What Does It Mean to Manage Non-Human Identities Effectively? Imagine where every digital entity, from simple applications to complex systems, functions like travelers in an international airport. If ...

Millions installed 'productivity' Chrome extensions that became malware after acquisition. Here's how browser extensions became enterprise security's weakest link.

After weeks of failed negotiations, public ultimatums, and lawsuit threats, the Defense Department has formally labeled ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

As data moves beyond institutional systems, higher education faces a growing challenge with shadow data. Here’s how IT leaders can identify, manage and govern it before it creates compliance risks.